We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Point-of-Care Breath Test Rapidly Detects Active H. pylori

By LabMedica International staff writers
Posted on 30 Jul 2013
A novel, nonradioactive breath test system for the qualitative detection of active Helicobacter pylori infection in symptom-presenting patients provides improved efficiency and accuracy for diagnosis and treatment monitoring. More...


Exalenz Bioscience (Modiin, Israel) offers its "BreathID Hp" test for noninvasive, presumptive detection of H. pylori (Hp). BreathID Hp is initially designed to support the needs of urgent care facilities, gastroenterologists, bariatric specialists, and PCPs. The ability to rapidly, conveniently, and accurately detect Hp in patients presenting with related symptoms "is an important addition to any physician's office or clinical laboratory," said Steven Eitan, CEO of Exalenz. BreathID Hp detects H. pylori in 10–15 minutes through a simple, single-step, nonradioactive 13C-urea based breath test. The BreathID System platform is capable of analyzing parts-per-million changes in carbon 13 and carbon 12 ratios in human breath. The device is of a compact, benchtop footprint and at 13.6 kg is easily transported.

There are currently three main types of Hp tests being used: blood, stool, and breath tests. Leading practice associations recommend the urea breath test (UBT). Blood and stool tests are somewhat invasive, take 1-3 days with significant lab processing costs, and blood tests are prone to false positives. Furthermore, eradicating Hp through treatment depends on accurate detection of active Hp infection at initial diagnosis and in post-treatment testing. “Given [...] the shortcomings of common blood tests for Hp, which do not accurately differentiate between active and prior infection, we believe we have a compelling offering to advance patient care,” said Mark Hood, Vice President of North American Sales for Exalenz. UBT is currently the most accurate noninvasive means for identifying active Hp infection.

In comparison to the cumbersome radioactive (14C) UBT at 96% sensitivity and specificity, with BreathID Hp a patient drinks a safe low dosage of nonradioactive 13C-labeled urea, then breaths normally into the device while it analyzes in real-time the continuous flow of fresh breath, then rapidly provides a 99% accurate written diagnosis report (real-time analysis is powered by the BreathID platform, which incorporates a number of proprietary core technologies). This enables an "informed" treatment protocol – allowing physicians to immediately prescribe treatment if deemed necessary, rather than prescribing potentially unnecessary preventative treatment "just in case" while waiting for 1–3 days and for less reliable results.

Exalenz provides two distinct offerings. One is the "Hp FasTest" performed with a dedicated BreathID System device located in a physician's regular or emergency room office, enabling point-of-care Hp testing. A non-rapid (1–3 days) but more centralized option will be the "Hp BagTest,” a send-in service at dedicated centers, initially in certain USA states. The first Breath Test Center is being established in cooperation with Metabolic Solutions, a company with 20 years’ experience in breath test-sample analysis. For establishment of channels to provide the device and kits in the USA, Mr. Dennis Boyle (previously of Siemens USA) has been appointed Vice-President and National Manager of Exalenz in the USA.

BreathID Hp is FDA-cleared in the USA and is CE-approved in Europe for diagnosing and treating H. pylori.

Related Links:

Exalenz Bioscience




New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
New
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.